The role of different adjuvant therapies in locally advanced gastric adenocarcinoma

Ilaria Benevento; Nadia Bulzonetti; Francesca De Felice; Daniela Musio; Massimo Vergine; Vincenzo Tombolini

doi:10.18632/oncotarget.26106

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Clinical Research Papers:

The role of different adjuvant therapies in locally advanced gastric adenocarcinoma

Ilaria Benevento _, Nadia Bulzonetti, Francesca De Felice, Daniela Musio, Massimo Vergine and Vincenzo Tombolini

PDF | HTML | How to cite

Oncotarget. 2018; 9:34022-34029. https://doi.org/10.18632/oncotarget.26106

Metrics: PDF 981 views | HTML 1292 views | ?

Abstract

Ilaria Benevento1,*, Nadia Bulzonetti1,*, Francesca De Felice1, Daniela Musio1, Massimo Vergine2 and Vincenzo Tombolini1

1Department of Radiotherapy, Policlinico Umberto I, Sapienza University of Rome, Rome 155, Italy

2Department of Surgical Sciences, Policlinico Umberto I, Sapienza University of Rome, Rome 155, Italy

*These authors contributed equally to this work

Correspondence to:

Ilaria Benevento, email: [email protected]

Keywords: adjuvant therapy; chemoradiotherapy; radiotherapy; gastric cancer

Received: May 29, 2018 Accepted: August 27, 2018 Published: September 21, 2018

ABSTRACT

Background and Purpose: Complete surgical resection remains the only curative treatment option in locally advanced gastric cancer (GC). Several studies were conducted to prevent local recurrence and to increase the chance of cure. The aim of this study was to summarize our experience in locally advanced GC patients treated with adjuvant chemoradiotherapy (CRT) and to evaluate overall survival (OS), disease-free survival (DFS), toxicity rate and compliance to treatment.

Materials and Methods: Locally advanced GC stage IB-III were included. Adjuvant CRT consisted of 45–50.4 Gy (1.8 Gy/day, 5 days/week) with concomitant Macdonald regimen (Mcd) or Epirubicin, Cisplatin and 5-Fluorouracil (ECF) scheme. Univariate and multivariate analysis of several prognostic factors for OS was conducted.

Results: Fourty-nine GC patients were treated: 24 received Mcd and 25 received ECF. Median follow up was 48 months. Acute grade 3–4 toxicity was observed in 6 patients. The 2-year and 5-year OS rates were 65.3% and 41.5%, respectively. The 2-year and 5-year DFS were 59.2% and 41.2%, respectively. No prognostic factors were significantly associated with OS.

Conclusions: Adjuvant CRT is a feasible strategy in locally advanced GC. It has an acceptable toxicity rate and it is able to increase both DFS and OS.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26106

Publication Alerts

Clinical Research Papers:

The role of different adjuvant therapies in locally advanced gastric adenocarcinoma

Abstract